Trials / Conditions / Refractory Chronic Cough

Refractory Chronic Cough

22 registered clinical trials studyying Refractory Chronic Cough — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough NCT06960759	University of Montana	Phase 2
Not Yet Recruiting	A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UC NCT07483489	Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.	Phase 2
Not Yet Recruiting	A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patient NCT07288528	McMaster University	Phase 4
Recruiting	Cough Management Wellness App for Refractory or Unexplained Chronic Cough NCT07070895	Hyfe Inc	N/A
Recruiting	Group Telehealth Behavioral Cough Suppression Therapy NCT06706765	University of Montana	EARLY_Phase 1
Unknown	A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough NCT06213363	Beijing Tide Pharmaceutical Co., Ltd	Phase 1 / Phase 2
Completed	Refractory Chronic Cough Improvement Via NAL ER (RIVER) NCT05962151	Trevi Therapeutics	Phase 2
Completed	A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough NCT05733533	Guangdong Hengrui Pharmaceutical Co., Ltd	Phase 2
Active Not Recruiting	A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough NCT05600777	Bellus Health Inc. - a GSK company	Phase 3
Active Not Recruiting	A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough NCT05599191	Bellus Health Inc. - a GSK company	Phase 3
Completed	Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients NCT05628740	Nocion Therapeutics	Phase 1
Recruiting	Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough NCT05110144	Mayo Clinic	Phase 2
Terminated	COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database NCT04882943	University Hospital, Toulouse	—
Completed	Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough NCT04678206	Bellus Health Inc. - a GSK company	Phase 2
Unknown	Indomethacin for Refractory Chronic Cough NCT03662269	The First Affiliated Hospital of Guangzhou Medical University	Phase 3
Completed	Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough NCT03282591	Vyne Therapeutics Inc.	Phase 2
Completed	An 8-Week Refractory Chronic Cough Study (MK-7264-021) NCT02612623	Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 2
Completed	A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) NCT02612610	Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 2
Completed	Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (M NCT02476890	Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 2
Completed	Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015) NCT02397460	Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 2
Completed	A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) NCT02349425	Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 2
Completed	Treatment of Refractory Chronic Cough With PA101 NCT02412020	Patara Pharma	Phase 2